Cargando…

Palonosetron-Induced Ventricular Tachycardia in a Patient Receiving Cancer Chemotherapy

Chemotherapy-induced nausea and vomiting (CINV) is one of the major and most distressing adverse effects of cancer chemotherapy. It is treated with various antiemetic regimens, of which one class of drugs is 5-hydroxytryptamine type 3 receptor antagonists (5-HT(3) RA). Palonosetron, a potent antieme...

Descripción completa

Detalles Bibliográficos
Autores principales:	M, Prasad, V K, Shashidar, Chakraborty, Ananya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602430/ https://www.ncbi.nlm.nih.gov/pubmed/28944119 http://dx.doi.org/10.7759/cureus.1480

Ejemplares similares

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy
por: Longo, F, et al.
Publicado: (2012)

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
por: Affronti, Mary Lou, et al.
Publicado: (2014)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)
por: Karthaus, Meinolf, et al.
Publicado: (2015)

Non-Sustained Ventricular Tachycardia as a Sign of Lung Cancer
por: Haq, Shujaul, et al.
Publicado: (2019)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
por: Boccia, Ralph, et al.
Publicado: (2013)

Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy
por: Lorusso, Vito, et al.
Publicado: (2012)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy
por: Minatogawa, Hiroko, et al.
Publicado: (2020)

Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
por: Sugawara, Shunichi, et al.
Publicado: (2019)

Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy
por: Toda, Haruka, et al.
Publicado: (2017)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
por: Cheng, Yi, et al.
Publicado: (2022)

Comparison of Palonosetron, Dexamethasone, and Palonosetron Plus Dexamethasone as Prophylactic Antiemetic and Antipruritic Drug in Patients Receiving Intrathecal Morphine for Lower Segment Cesarean Section
por: Swaro, Swastika, et al.
Publicado: (2018)

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
por: Fujiwara, Satoe, et al.
Publicado: (2015)

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
por: Janicki, Piotr K
Publicado: (2016)

The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting
por: HUANG, JIAN, et al.
Publicado: (2013)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016)

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
por: Boccia, Ralph, et al.
Publicado: (2016)

A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy
por: Yuan, Hai-Liang, et al.
Publicado: (2021)

Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
por: Kim, Jin Soo, et al.
Publicado: (2014)

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
por: Shimizu, Hisanori, et al.
Publicado: (2018)

Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis
por: Li, Nannan, et al.
Publicado: (2020)

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
por: Zilioli, Vittorio R, et al.
Publicado: (2020)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin
por: Oyama, Katsunobu, et al.
Publicado: (2015)

Ventricular Dysfunction: Tachycardia induced Cardiomyopathy
por: Ramesh Iyer, V
Publicado: (2008)

SBRT of ventricular tachycardia using 4pi optimized trajectories
por: Q. M. Reis, Cristiano, et al.
Publicado: (2021)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Ventricular tachycardia or supraventricular tachycardia?
por: Alasti, Mohammad, et al.
Publicado: (2022)

Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy
por: Sadaba, Belen, et al.
Publicado: (2014)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Stereotactic Arrhythmia Radioablation (STAR) of Ventricular Tachycardia: A Treatment Planning Study
por: Wang, Lei, et al.
Publicado: (2016)

Ondansetron induced fatal ventricular tachycardia
por: Chandrakala, R., et al.
Publicado: (2008)

Bidirectional ventricular tachycardia of unusual etiology
por: Chakraborty, Praloy, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_icja1si3r1u58eru33qe8if1bi